Form 4: Amgen Executive Matthew C. Busch Reports Acquisition of Common Stock

Matthew C. Busch, VP of Finance & CAO at Amgen, reports the acquisition of 418 shares of common stock on March 6, 2024.

Summary

• On March 6, 2024, Matthew C. Busch, VP of Finance & CAO at Amgen, acquired 418 shares of Amgen's common stock.
• Following the transaction, Busch directly owns 4,799 shares of Amgen common stock.
• These shares include restricted stock units (RSUs) that will vest at various dates in the future.
• The RSUs will vest in installments on various dates in 2024, 2025, 2026 and 2027.
• Vested RSUs will be paid in shares of Amgen's common stock on a one-to-one basis.
• The reported shares also include 115 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan.
• DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction disclosure.

Positives

• The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company executive.

Key Dates